GCs Major Driver of Depression in SLE Ab#1446 #ACR23 @RheumNow 1463 pts with SLE, prospective longitudinal study GC use: 49-57% of pts Prevalence of depression at any time: 89.8%, most of time 35%!! Risk factors: - Fibromyalgia OR 2.9 - GC OR 1.85

PRES in SLE A#1478 @RheumNow #ACR23 303 cases of Posterior Reversible Encephalopathy Syndrome in SLE - Mean age 28, 91% F - 42% HTN, HLD 15%, DM 10% - 83% lupus nephritis. 80% dsDNA, 41% Sm, 38% aPL - 78% seizures - 3% mortality - Transient in 45%, persistent in 19%, 8% sequelae

Vasculitis in SLE A#1443 @RheumNow #ACR23 804 SLE pts, 74% black, 9.5% h/o vasculitis 45% visceral vasculitis, 43% cutanous, 8% both Pts w vasculitis: younger age of SLE dx- 27 v 31y Risks: other SARD, renal dx, neuro dx, low compl Trend to higher mortality 21 to 14% (no signif)

Fate of ANA+/UCTD A#1449 #ACR23 @RheumNow 207 asymptomatic ANA+ or UCTD followed - <10% progress to SARD, 90% did not Progression to SLE (11 pt), Sjo (5), SSc (3), RA (1) Progressors to SLE: arthritis (91%), low compl (45%), alopecia (36%), ulcers (27%) - milder manifestations

SGLT2 inhibitors compared to DPP4i may be better at reducing risk for MACE & renal progression in patients with SLE/LN and diabetes. SGLT2i risk for MACE (HR 0.69, 95% CI 0.48-0.99), and renal progression (HR 0.71, 95% CI 0.51-0.98). abst# 1579 #ACRbest #ACR23 @rheumnow

#ACR23 Abstr#1512 Can we improve trial design of Bcell depletion in #SLE? Feasibility RCT of RTX in organ specific MSK showed: a) feasible to use ultrasound & clinical as endpoints, b) new tool LAMDA is responsive, c)potential worsening before later improvement with RTX @RheumNow https://t.co/YmbUOWVdWS

Do you discuss HPV vax & cervical CA screening w/SLE & RA pts? In this study, more women w/SLE discussed cervical CA screening w/their rheums(33.3% vs. 11.4% p<0.01) & more likely to have persistent abn paps on ffup Similar HPV vax status for both grps #ACR23 ABST1356 @RheumNow https://t.co/Vbu8hbZ1uh

#ACR23 Abstr#1509 SLR & Meta-Analysis of RCTs in lupus nephritis (N=16 studies): -CNI (VOC/TAC/CyA) alone (OR 1.4) or combined MMF (OR 2.1) was assoc with CR vs SOC (MMF/Cyclo) -Less GI AEs & cytopenia in CNI Assuring data esp when cost is a hurdle for VOC @RheumNow #ACRBest https://t.co/9ScakIdXBN

#ACR23 Abstr#1479 In N=66 patients with #SLE, 29% had high risk HPV infection. Associated with lupus disease duration. In 2nd screening ~1yr after, multiple infections occurred in 15%, about similar vs women with HIV. Call to promote HPV vaccination in SLE 💉 @RheumNow https://t.co/UGIrCwu32x

#ACR23 Abstr#1579 More data on the role of SGLT2-i in #SLE. Data from EHR using propensity match scoring showed the use of SGLT2-i vs DPP4-i (for nonSLE indication) was associated with reduced risk of MACE (HR:0.69)and poor renal outcomes inc. ESRD (HR:0.71) @RheumNow https://t.co/7k0o3m18AN

In their cohort, Dr. Jorge reports that SLE pts who used SGLT2i had⬇️risk of MACE(HR 0.69 [95% CI 0.48-0.99]) & renal progression(HR 0.71 [95% CI 0.51-0.98]) vs DPP4 use Risk of MACE also⬇️in LN subgrp 🧐💊A potential role of SGLT2i for SLE/LN? #ACR23 ABST1579 @RheumNow #ACRbest https://t.co/Dod8DqRvLo

#ACR23 @RheumNow SGLT2 inhibitors help CV & renal outcomes, but SLE pts excluded @AprilJorgeMD ComparedSGLT2 to DPP4 inhibs, real world observation emulation study in SLE pts with T2DM Lower incidence of MACE & renal progression Subgroup w LN - risk reduction 10.2 MACE/100 py https://t.co/JpJ0yWNQBe